{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:48Z","timestamp":1791355788437,"version":"4.3.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Antibody\u2013drug conjugates (ADCs) are being investigated in advanced small-cell lung cancer (SCLC), but the evidence is dominated by early-phase studies conducted in non-exchangeable treatment settings. We evaluated the activity and toxicity of ADCs while separating later-line monotherapy from frontline combination therapy, later-line combination therapy, and post-induction maintenance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, the Cochrane Library, and Web of Science Core Collection were searched from inception and in 28 August 2026. ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) were searched on 28 August 2026. We constructed an arm-level dataset that recorded regimen, dose, clinical context, target, outcome definition, numerator, denominator, analysis set, and source. The primary quantitative synthesis was restricted to second-line or later ADC monotherapy; other clinical contexts were summarized descriptively. Single-arm proportions were synthesized using a binomial\u2013normal random-intercept generalized linear mixed model on the logit scale. We reported 95% confidence intervals (CIs), between-study variance, heterogeneity, and 95% prediction intervals. An inverse-variance logit random-effects model with restricted maximum likelihood estimation and Hartung\u2013Knapp inference was used as a sensitivity analysis. Fixed-time Kaplan\u2013Meier survival estimates and inconsistently defined common adverse events were not pooled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>16 trial families evaluating eight ADCs across five target classes met the eligibility criteria. In the primary later-line monotherapy analysis, the pooled ORR was 25.7% (95% CI, 16.4%\u201337.9%), and the pooled DCR was 72.7% (95% CI, 60.7%\u201382.2%). The pooled incidences of grade \u22653 TEAEs and grade \u22653 TRAEs were 62.8% (95% CI, 59.6%\u201365.9%) and 45.5% (95% CI, 35.5%\u201356.0%), respectively. The prediction intervals for ORR, DCR, and grade \u22653 TRAEs were wide. Proportions observed in a new study may therefore differ substantially from the pooled estimates. Frontline combinations, later-line combinations, and maintenance therapy yielded context-specific signals but were not compared with later-line monotherapy. Target-stratified analyses were exploratory; B7-H3 and DLL3 estimates were based on small, non-comparative groups, whereas Trop-2 and SEZ6 were not pooled because fewer than three studies were available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Later-line ADC monotherapy showed antitumor activity but frequent clinically important toxicity, with substantial between-study variation. The evidence does not establish superiority by treatment line, regimen, agent, or molecular target; single-arm response estimates also do not demonstrate a survival benefit. Randomized, context-specific trials using harmonized efficacy and safety definitions are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1929911","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:51:51Z","timestamp":1791352311000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody\u2013drug conjugates in advanced small-cell lung cancer: a systematic review and single-arm meta-analysis of later-line monotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinmiao","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital and Yuying Children\u2019s Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The Second Affiliated Hospital and Yuying Children\u2019s Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital and Yuying Children\u2019s Hospital of Wenzhou Medical University","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.07.007","article-title":"What's new in SCLC? A review","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"von Pawel","year":"2014","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116378","article-title":"Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation","volume":"226","author":"Zhao","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104189","article-title":"The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review","volume":"192","author":"Filis","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/CCO.0000000000000656","article-title":"Antibody-drug conjugates in breast cancer: the chemotherapy of the future","volume":"32","author":"Nicolo","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody-drug conjugates: Promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"MAbs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: Results from TROPiCS-03","volume":"20","author":"Dowlati","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: Primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-24-1547","article-title":"A phase I first-in-human study of ABBV-011, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in patients with small cell lung cancer","volume":"30","author":"Morgensztern","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8093","article-title":"ARTEMIS-001: Data from a phase 1a\/b study of HS-20093 in patients with relapsed small-cell lung cancer","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: Results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.04.017","article-title":"SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study","volume":"145","author":"Morgensztern","year":"2020","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: Results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100405","article-title":"Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer","volume":"28","author":"Calvo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-0933","article-title":"Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan","volume":"23","author":"Gray","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage- SCLC: Results from the phase 3 MERU study","volume":"16","author":"Johnson","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cllc.2016.09.002","article-title":"Phase 1\/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin\/etoposide in small-cell lung cancer patients with extensive-stage disease","volume":"18","author":"Socinski","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.022","article-title":"A phase 1 study evaluating rovalpituzumab tesirine in frontline treatment of patients with extensive-stage SCLC","volume":"16","author":"Hann","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.022","article-title":"A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC","volume":"16","author":"Malhotra","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.07.025","article-title":"Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer","volume":"135","author":"Udagawa","year":"2019","journal-title":"Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3981","article-title":"Multidimensional analysis of B7 homolog 3 RNA expression in small cell lung cancer molecular subtypes","volume":"31","author":"Gay","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S359","DOI":"10.1016\/j.jtho.2024.09.646","article-title":"P3.13D.01 proteomic characterization of antibody drug conjugate target expression profiles in small cell lung cancer (SCLC)","volume":"19","author":"Lin","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108425","article-title":"Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis","volume":"201","author":"He","year":"2025","journal-title":"Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf332","article-title":"Antibody drugs conjugates in small-cell lung cancer: present-day status and promises","volume":"30","author":"Syal","year":"2025","journal-title":"Oncologist"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2026.103091","article-title":"Targeted precision strike in extensive-stage small cell lung cancer: Current advances and future perspectives for antibody-drug conjugates","volume":"143","author":"Li","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189445","article-title":"The evolving landscape of antibody-drug conjugates in small cell lung cancer: From research progress to clinical application","volume":"1880","author":"Wang","year":"2025","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biology14121677","article-title":"Unlocking new horizons: Antibody-drug conjugates in small cell lung cancer","volume":"14","author":"Liu","year":"2025","journal-title":"Biol (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1929911\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:51:52Z","timestamp":1791352312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1929911\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1929911"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1929911","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1929911"}}